Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.

NCT03267173 is registered in ClinicalTrials.gov with First Affiliated Hospital of Harbin Medical University as lead sponsor.

NCT NCT03267173
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03267173 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.
Lead sponsor
First Affiliated Hospital of Harbin Medical University
Phase
Phase 1
Overall status
Unknown status
Start date
June 15, 2017
Completion date
June 30, 2019
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

car, pancreatic cancer